.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
ZeroHarm Sciences recently raised Rs 65 crore to scale its innovative plant-based nutraceutical brand. Consequently, this capital infusion from Kotak Life Sciences Fund and Alkemi Growth Capital marks a major milestone. The company intends to enhance its research capabilities and global reach.
Specifically, ZeroHarm uses proprietary nano-formulation technology to increase the bioavailability of its supplements. This method ensures that herbal actives are absorbed more effectively by the body. Furthermore, the firm is building India's first \"Trust over Promise\" health platform. This model correlates supplement use with measurable diagnostic results.
Additionally, the startup plans to enter markets in the US, UK, and the Middle East. ZeroHarm maintains a vertically integrated ecosystem, covering extraction, R&D, and manufacturing. Notably, this structure allows for strict quality control and standardized health outcomes. Because of these factors, investors see high potential in the company’s science-led approach.
Q1: What is the \"Trust over Promise\" platform?
The \"Trust over Promise\" platform allows customers to see measurable health outcomes through before-and-after diagnostic testing.
Q2: How does nano-formulation technology benefit patients?
Nano-formulation breaks down herbal actives into ultra-fine particles, which significantly improves their absorption and efficacy compared to traditional supplements.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ZeroHarm Sciences raised Rs 65 crore to expand its plant-based nutraceutical brand using nano-technology and a diagnostic-led health outcome model....
6 months ago
A nationwide study reveals stable pathogen specification rates in infectious diarrhea hospitalizations from 2016 to 2023, accompanied by a marked decline in Clostridioides difficile cases, emphasizing the need for targeted diagnostic stewardship and thoughtful multiplex testing in hospital medicine.
3 days back
A real-world cohort study evaluates anti-Müllerian hormone recovery and fertility outcomes in high-risk GTN patients treated with EMA/CO versus FAEV chemotherapy, demonstrating robust ovarian reserve recovery by six months post-treatment.
4 days back
A real-world Japanese claims database analysis reveals that the 2021 heart failure guideline update drove significant improvements in guideline-directed medical therapy (GDMT). The study highlighted substantial increases in the prescription of sacubitril/valsartan and dapagliflozin among heart failure patients.
4 days back
A multicenter prospective cohort study reveals that 54.1% of patients achieve clinically meaningful neuropathic pain relief after surgery for degenerative cervical myelopathy, driving substantial gains in motor function, mental health, and quality of life.
3 days back
The ferroptosis-immunity axis represents a critical driver of diabetic kidney disease progression. This review explores iron-dependent lipid peroxidation, innate immune cross-talk, emerging candidate biomarkers, and promising targeted therapies to delay renal decline alongside standard glycemic control.
4 days back
